AR085778A2 - Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato - Google Patents

Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato

Info

Publication number
AR085778A2
AR085778A2 ARP120101574A ARP120101574A AR085778A2 AR 085778 A2 AR085778 A2 AR 085778A2 AR P120101574 A ARP120101574 A AR P120101574A AR P120101574 A ARP120101574 A AR P120101574A AR 085778 A2 AR085778 A2 AR 085778A2
Authority
AR
Argentina
Prior art keywords
mycophenolic acid
solid dose
mycophenolate salt
dose form
form covered
Prior art date
Application number
ARP120101574A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085778(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR085778A2 publication Critical patent/AR085778A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una forma de dosis sólida entérica revestida que comprende una cantidad farmacológicamente efectiva de ácido micofenólico o sal micofenolato, donde el ácido micofenólico o la sal micofenolato está presente en una cantidad de desde 20% hasta 80% en peso en base al peso total de la forma de dosis sólida incluyendo el revestimiento entérico, donde la forma de dosis sólida es una tableta que contiene ácido micofenólico o sal micofenolato en forma sustancialmente anhidra, proceso para su preparación, tableta y uso de dicha forma para preparar medicamentos.
ARP120101574A 2001-10-17 2012-05-04 Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato AR085778A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds

Publications (1)

Publication Number Publication Date
AR085778A2 true AR085778A2 (es) 2013-10-30

Family

ID=9924043

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020103852A AR036813A1 (es) 2001-10-17 2002-10-15 Composiciones farmaceuticas
ARP120101574A AR085778A2 (es) 2001-10-17 2012-05-04 Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020103852A AR036813A1 (es) 2001-10-17 2002-10-15 Composiciones farmaceuticas

Country Status (31)

Country Link
US (3) US20050013859A1 (es)
EP (1) EP1438040B2 (es)
JP (2) JP2005508959A (es)
KR (1) KR100671367B1 (es)
CN (1) CN1310640C (es)
AR (2) AR036813A1 (es)
AT (1) ATE374023T1 (es)
AU (1) AU2002338897B2 (es)
BR (1) BR0213355A (es)
CA (1) CA2460574A1 (es)
CO (1) CO5390076A1 (es)
CY (1) CY1107841T1 (es)
DE (1) DE60222687T3 (es)
DK (1) DK1438040T4 (es)
EC (2) ECSP024341A (es)
ES (1) ES2292819T5 (es)
GB (1) GB0124953D0 (es)
HU (1) HU231114B1 (es)
IL (2) IL160968A0 (es)
MX (1) MXPA04003636A (es)
MY (1) MY139206A (es)
NO (1) NO341804B1 (es)
NZ (1) NZ532280A (es)
PE (1) PE20030476A1 (es)
PL (2) PL415001A1 (es)
PT (1) PT1438040E (es)
RU (2) RU2338528C2 (es)
SI (1) SI1438040T2 (es)
TW (1) TWI333861B (es)
WO (1) WO2003032978A1 (es)
ZA (1) ZA200401977B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
TWI322147B (en) * 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
EP1940388A2 (en) * 2005-09-30 2008-07-09 Novartis AG Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection
US8597679B2 (en) 2005-12-21 2013-12-03 Basf Se Fine-particle crosslinked polyvinylpyrrolidone as tablet disintegrant
KR20080094788A (ko) * 2006-02-13 2008-10-24 노파르티스 아게 고복용량의 미코페놀산(엠피에이)
EP2164460B1 (de) 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
EP2164462B1 (de) 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
AU2008288106B2 (en) * 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
CN101969931A (zh) * 2008-03-05 2011-02-09 万能药生物有限公司 包含霉酚酸的调节释放药物组合物及其方法
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
MX2019010829A (es) * 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators
AU2021424131B2 (en) * 2021-01-28 2026-08-13 Priothera Limited Methods of treatment with s1p receptor modulators
WO2022250977A1 (en) * 2021-05-26 2022-12-01 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
EP0670724A1 (en) * 1992-11-24 1995-09-13 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
CN1047075C (zh) * 1993-02-26 1999-12-08 普罗克特和甘保尔公司 比沙可啶剂型
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
EP0724441A1 (en) * 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
JP2003525052A (ja) * 2000-02-29 2003-08-26 バイオコン・インディア・リミテッド マイコフェノール酸の製造および精製
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ATE374023T1 (de) 2007-10-15
CN1564684A (zh) 2005-01-12
TWI333861B (en) 2010-12-01
PL367738A1 (en) 2005-03-07
NO20041785L (no) 2004-05-03
IL160968A (en) 2016-04-21
DE60222687T3 (de) 2020-03-05
DE60222687T2 (de) 2008-07-17
EP1438040B2 (en) 2019-10-16
DE60222687D1 (de) 2007-11-08
ECSP024341A (es) 2003-12-01
RU2007130786A (ru) 2009-02-20
EP1438040A1 (en) 2004-07-21
IL160968A0 (en) 2004-08-31
RU2004115332A (ru) 2005-04-20
DK1438040T4 (da) 2020-01-27
PT1438040E (pt) 2008-01-02
SI1438040T2 (sl) 2020-02-28
RU2381026C2 (ru) 2010-02-10
AU2002338897B2 (en) 2006-10-19
GB0124953D0 (en) 2001-12-05
SI1438040T1 (sl) 2008-04-30
RU2338528C2 (ru) 2008-11-20
KR100671367B1 (ko) 2007-01-19
HU231114B1 (hu) 2020-09-28
PL234541B1 (pl) 2020-03-31
ES2292819T5 (es) 2020-05-29
HUP0600451A2 (en) 2006-09-28
MY139206A (en) 2009-08-28
CN1310640C (zh) 2007-04-18
PE20030476A1 (es) 2003-07-30
JP2009137996A (ja) 2009-06-25
JP2005508959A (ja) 2005-04-07
ES2292819T3 (es) 2008-03-16
WO2003032978A1 (en) 2003-04-24
HK1067861A1 (en) 2005-04-22
AR036813A1 (es) 2004-10-06
NO341804B1 (no) 2018-01-22
US20050013859A1 (en) 2005-01-20
MXPA04003636A (es) 2004-07-27
US20100210717A1 (en) 2010-08-19
DK1438040T3 (da) 2008-02-04
US20120237601A1 (en) 2012-09-20
NZ532280A (en) 2007-05-31
CY1107841T1 (el) 2013-06-19
ZA200401977B (en) 2006-05-31
CA2460574A1 (en) 2003-04-24
KR20050037409A (ko) 2005-04-21
ECSP024342A (es) 2003-03-10
PL415001A1 (pl) 2016-02-29
CO5390076A1 (es) 2004-04-30
EP1438040B1 (en) 2007-09-26
BR0213355A (pt) 2006-05-23

Similar Documents

Publication Publication Date Title
AR036813A1 (es) Composiciones farmaceuticas
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
AR042472A1 (es) Preparaciones de liberacion controlada que comprenden tramadol y topiramato
UY27740A1 (es) Nuevos compuestos
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
BR0209579A (pt) Derivados de 2-piridina ciclohexana-1, 4 diamina substituìdos
MX9201730A (es) Nuevos fenilazacicloalcanos substituidos que actuan centralmente.
UY30440A1 (es) Nuevos compuestos
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
NO20000466L (no) Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
AR002265A1 (es) Soluciones para inyeccion o infusion que comprenden enrofloxaxin y su procedimiento de preparacion
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
BR0315320A (pt) Composto ou sais farmaceuticamente aceitáveis dos mesmos, uso de um composto, composição farmacêutica, e, métodos para a terapia de dor em um animal de sangue quente e para produzir um composto
SE0102440D0 (sv) New compound
AR014714A1 (es) Sales de cetoacidos y derivados de aminas, y su utilizacion para la preparacion de medicamentos
NO954952D0 (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos

Legal Events

Date Code Title Description
FC Refusal